Kailera Therapeutics, Inc. Common Stock (KLRA) Stock Price

KLRAStock
$16.21
Market Cap$2.10B
P/E
PEG Ratio
Div yield
Beta2.14

KLRA Share Price Chart

Favorite Metrics

Price vs S&P 500 (4W)-7.95%
VGM Score26.67

KLRA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.76-$1.09-43.42%(-$0.33)
Q1 2026-$0.55-$3.65-565.09%(-$3.10)

KLRA Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
4.22
4.30
4.33

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
KLRAKailera Therapeutics, Inc. Common Stock
D$16.21
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Kailera Therapeutics, Inc. Common Stock

Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.